Somewhat Positive Media Coverage Somewhat Unlikely to Impact Agenus (AGEN) Share Price
News articles about Agenus (NASDAQ:AGEN) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Agenus earned a news impact score of 0.16 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 45.2363689682178 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Agenus (AGEN) opened at $3.65 on Monday. Agenus has a 52 week low of $3.20 and a 52 week high of $5.45. The firm has a market capitalization of $372.17, a price-to-earnings ratio of -3.12 and a beta of 2.10. The company has a current ratio of 1.55, a quick ratio of 1.55 and a debt-to-equity ratio of -2.39.
AGEN has been the topic of a number of recent analyst reports. Zacks Investment Research raised Agenus from a “hold” rating to a “buy” rating and set a $4.50 price target on the stock in a research note on Tuesday, January 9th. BidaskClub raised Agenus from a “strong sell” rating to a “sell” rating in a research note on Friday. Finally, ValuEngine lowered Agenus from a “sell” rating to a “strong sell” rating in a research note on Friday, December 29th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $5.81.
Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.